Last reviewed · How we verify
standard concomitant therapy
Standard concomitant therapy involves administering multiple medications together to treat a condition.
Standard concomitant therapy involves administering multiple medications together to treat a condition. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | standard concomitant therapy |
|---|---|
| Sponsor | R-Pharm |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of standard concomitant therapy is not well-defined, as it typically involves a combination of medications with different mechanisms of action. Each medication in the combination may have a different target or mechanism, but together they work to achieve a therapeutic effect.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Anorexia
- Weight loss
- Hypertension
Key clinical trials
- Prevent TB: Choice Architecture for TPT Delivery (NA)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis (PHASE2, PHASE3)
- DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) (PHASE2)
- Colonic Delivery of DIM and Perilla Oil on Gut Hormones and Food Intake in Obesity (NA)
- D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard concomitant therapy CI brief — competitive landscape report
- standard concomitant therapy updates RSS · CI watch RSS
- R-Pharm portfolio CI